Technosphere insulin: Inhaled prandial insulin

Expert Opinion on Biological Therapy

Volumn 16, Issue 1, 2016, Pages 111-117

  Setji, Tracy L ^a   Hong, Beatrice D ^a   Feinglos, Mark N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Affinity; Afrezza; Exubera; Gen2; inhaled insulin; insulin; MedTone; prandial; technosphere

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

BLOOD; CHEMICALLY INDUCED; CHEMISTRY; DIABETES MELLITUS; DRUG EFFECTS; HUMAN; HYPOGLYCEMIA; INHALATIONAL DRUG ADMINISTRATION; MEAL; METABOLISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MEALS; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 84955681104     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1121230     Document Type: Review

References (28)

1. 2014 National diabetes statistics report. [. cited 2015 Aug 16 ]. Available from http://www. cdc.gov/diabetes/data/ statistics/ 2014statist icsreport.html
2. Peyrot M, Rubin RR, Kruger DF., et al. Correlated of insulin injection omission. Diabetes Care. 2010; 33: 240-245
3. Polonsky WH, Fisher L, Guzman S., et al. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care. 2005; 28: 2543-2545
4. Peyrot M, Rubin RR, Lauritzen T., et al. Resistance to insulin therapy among patients and providers. Diabetes Care. 2005; 28: 2673-2679
5. Selam JL. Inhaled insulin: promises and concerns. J Diabetes Sci Technol. 2008; 2: 311-315
6. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004; 1: 338-344
7. Mandal T. Inhaled insulin for diabetes mellitus. Am J Health-Syst Pharm. 2005; 62: 1359-1364
8. McMahon GT, Arky RA. Inhaled insulin for diabetes mellitus. N Engl J Med. 2007; 356: 497-502
9. AFREZZA [package insert]. Valencia, CA: MannKind Corporation; 2015. [. cited 2015 Aug 16 ]. Available from: http://products.sanofi.us/afrezza/afrezza.pdf
10. Potocka E, Cassidy JP, Haworth P., et al. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol. 2010; 4: 1164-1173
11. Cassidy PL, Amin N, Marino M., et al. Insulin lung deposition and clearance following technosphere insulin inhalation powder administration. Pharm Res. 2011; 28: 2157-2164
12. Neumiller JJ. Campbel RK and Wood LD. A review of inhaled technosphere insulin. Ann Pharmacother. 2010; 44: 1231-1239
13. Rave K, Potocka E, Heinemann L., et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009; 11: 715-720
14. An inhaled insulin: Afrezza. Med Lett Drugs Ther. 2015; 57: 34-35
15. Baughman R, Cassidy J, Levy B., et al. Technosphere insulin (TI) pharmacokinetics unchanged in subjects who smoke (abstract 427-P). Diabetes. 2008; 57: A128
16. Fountaine R, Milton A, Checchio T., et al. Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. Br J Clin Pharmacol. 2008; 65 (6): 864-870
17. MannKind Corporation. Briefing document: Endocrinologic and Metabolic Drugs Advisory Committee, April 01, 2014. [. cited 2015 Aug 17 ]. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommittesMeetingMaterial/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390865.pdf
18. Bode BW, McGill JB, Lorber DL., et al. Inhaled technosphere insulin compared with injected prandial insulin in tpe 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38:2266-2273
19. Rosenstock J, Franco D, Korpachev V., et al. Inhaled technosphere insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately contolled on oral antidiabetes agents. Diabetes Care. 2015;38:2274-2281
20. Rosenstock J, Bergenstal R, DeFronzo AR., et al. Efficacy and safety of technosphere inhaled insulin compared with technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008; 31: 2177-2182
21. Tack CJ, Vladimir C, De Galan BE., et al. Randomized forced titration to different doses of Technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol. 2008; 2: 47-57
22. Kapsner P, Bergenstal RM, Rendell M., et al. Comparative efficacy and safety of technosphere insulin and a rapid-acting analog both given with glargine in subjects with T1DM in a 52-week study. Diabetologia. 2009; 52 (Suppl 1):S386
23. Rosenstock J, Lorber DL, Gnudi L., et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicenter randomized trial. Lancet. 2010; 375: 2244-2253
24. Raskin P, Heller S, Honka M., et al. Pulmonary function over two years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obesity Metab. 2012; 14: 163-173
25. Peyrot M, Rubin RR. Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther. 2010; 12: 49-55
26. Peyrot M, Rubin RR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled Technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther. 2011; 13: 1201-1206
27. Ahren B, Holst JJ. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes. 2001; 50: 1030-1038
28. Zisser H, Dassau E, Lee JL., et al Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. J Diabetes Sci Technol. 2015; 9: 564-572